Moderna

Moderna is a pharmaceutical company currently facing scrutiny regarding its new mRNA flu vaccine. The FDA initially refused to review Moderna's application for the vaccine, citing concerns over the clinical trial's success, with some experts alleging political motivations behind the decision. This refusal raised concerns about the future of vaccine development and approval processes in the US, particularly given a perceived rollback of vaccine guidance by federal agencies. The FDA's initial decision caused Moderna's stock to tumble amidst existing concerns about declining COVID-19 vaccine sales. However, the FDA has since reversed its decision and will now review Moderna's flu vaccine application. This situation is significant as it highlights potential challenges and uncertainties in the vaccine approval process and raises questions about the role of political influence in regulatory decisions.